AmMax Bio's Participation at Major Healthcare Conference
AmMax Bio, Inc., a clinical-stage biopharmaceutical company renowned for its contributions to oncology, is making waves with its upcoming presentation at the esteemed Oppenheimer Healthcare Private Company Showcase. Set in New York City, this event will take place soon, marking an important milestone for the company as it seeks to highlight its innovative approach and groundbreaking research in the field of cancer treatment.
Company Overview Presentation
Andrew Sauter, the Chief Financial Officer of AmMax Bio, will deliver an insightful overview of the company. He is scheduled to present at a strategic time, during the afternoon, allowing for potential investor interactions that could shape the future of the company. This showcase offers a unique platform for AmMax Bio to engage with investors who are keen on the latest advancements in healthcare technology.
Advancements in Oncology: AMB-066
A centerpiece of AmMax Bio's pipeline is the AMB-066 program, which targets colorectal cancer with minimal residual disease (CRC MRD). As the company gears up for the initiation of a phase 2 proof of concept study, it's evident that AmMax is on the forefront of developing solutions in an area where conventional therapies have yet to make a significant impact. The goal is to enroll patients in this promising study shortly.
Colorectal Cancer with Minimal Residual Disease
Colorectal cancer with minimal residual disease presents a challenging reality for many patients. Approximately 20,000 individuals face this situation annually after undergoing definitive therapies. CRC MRD patients have detectable circulating tumor DNA (ctDNA+) but no visible signs of cancer through imaging. This group is at high risk for recurrence, primarily affecting critical organs such as the liver. Given the absence of approved therapies for CRC MRD, AmMax Bio's innovative approach offers hope for new treatment avenues.
The Role of AMB-066 in Treatment
AMB-066 utilizes a potent monoclonal antibody designed to engage the colony stimulating factor 1 receptor (CSF1R), directly addressing CRC MRD. This antibody has undergone rigorous testing across various indications and has demonstrated a favorable safety profile in around 200 patients. With its varied administration methods, including intravenous and subcutaneous injections, AMB-066 is positioned to change the therapeutic landscape significantly.
About AmMax Bio Inc.
Founded by Dr. Larry Hsu in 2020, AmMax Bio is dedicated to tackling the pressing needs of cancer patients through innovative drug development. Their unique CSF1R-targeting platform is the cornerstone of a robust pipeline that not only includes AMB-066 but also features AMB-051 and AMB-104. AMB-051 targets the tenosynovial giant cell tumor, while AMB-104 is aimed at treating acute myeloid leukemia. AmMax Bio's commitment to advancing cancer therapies underscores the potential for great advancements in treating these diseases.
Contact AmMax Bio, Inc. Andrew Sauter, CFO Email: andrewsauter@ammaxbio.com Tel: 650-787-3777
Frequently Asked Questions
What is AmMax Bio's main focus?
AmMax Bio focuses on developing innovative therapeutics in oncology, particularly targeting colorectal cancer with minimal residual disease.
What is the significance of AMB-066?
AMB-066 is a therapeutic designed to treat colorectal cancer patients who have minimal residual disease, providing a novel approach where few options exist.
When will the presentation at Oppenheimer take place?
The presentation by Andrew Sauter is scheduled for a notable time in the afternoon at the Oppenheimer Healthcare Private Company Showcase.
Who founded AmMax Bio?
AmMax Bio was founded by Dr. Larry Hsu in 2020, aiming to create innovative cancer therapies.
What other programs are in AmMax Bio's pipeline?
In addition to AMB-066, AmMax is developing AMB-051 for tenosynovial giant cell tumors and AMB-104 for acute myeloid leukemia.
